77,403 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Purchased by Transamerica Financial Advisors LLC

Transamerica Financial Advisors LLC acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 77,403 shares of the biotechnology company’s stock, valued at approximately $6,309,000. Transamerica Financial Advisors LLC owned 0.05% of Arrowhead Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Corient Private Wealth LP purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $1,313,000. Ausdal Financial Partners Inc. purchased a new stake in Arrowhead Pharmaceuticals in the second quarter worth $385,000. Jupiter Topco LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth $99,623,000. Hsbc Holdings PLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at $16,765,000. Finally, Osterweis Capital Management Inc. bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth about $4,101,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 0.3%

NASDAQ:ARWR opened at $89.12 on Thursday. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The stock has a market capitalization of $12.55 billion, a P/E ratio of -39.61 and a beta of 1.27. The company’s 50-day simple moving average is $83.44 and its 200-day simple moving average is $73.29. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $21.06 and a fifty-two week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The firm had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.Arrowhead Pharmaceuticals’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.26) earnings per share. On average, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director directly owned 31,600 shares in the company, valued at $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by insiders.

Analysts Set New Price Targets

ARWR has been the subject of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Piper Sandler reissued an “overweight” rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. Finally, Sanford C. Bernstein lifted their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $97.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.